Australia has an increasing demand for specialist contract formulation and manufacturing facilities to provide bespoke pharmaceutical products that meet regulatory and quality control standards.
The project will establish a unique and specialist manufacturing and training facility, Ab-initio, that provides cost effective manufacturing solutions for small-medium-enterprises (SMEs), academics, clinicians and larger pharma for early phase clinical trials in Australia. The consortium members hope that this project will assist Australia’s position as a global leader in the pharmaceutical sector.
Visit The University of Sydney for more information.
LinkedIn: The University of Sydney
|Consortium lead||The University of Sydney|
|Consortium members||Ab Initio Pharma, Sydney Local Health District (SLHD) & ARCS Australia|
|Project duration||June 2018 - 30 June 2021|
|Contact||Paul Young, The University of Sydney - firstname.lastname@example.org|